Company profile: CuraSen Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies for neurodegenerative diseases, developing orphan drugs including CST-103/CST-107, a combination therapy targeting cognitive symptoms and disease progression in Parkinson’s disease (Phase 2); CST-2032/CST-107 for Alzheimer’s disease with similar focus (Phase 2); and CST-3056, an alpha-1A adrenoceptor agonist in preclinical development.
Products and services
- CST-2032/CST-107: Phase 2 clinical-stage combination therapy for Alzheimer’s disease, pairing CST-2032 with CST-107 to address cognitive symptoms and disease progression
- CST-103/CST-107: Phase 2 clinical-stage combination therapy for Parkinson’s disease, integrating CST-103 with CST-107 to target cognitive symptoms and disease progression
- CST-3056: Preclinical-stage alpha-1A adrenoceptor agonist for neurodegenerative disease treatment, engaging the alpha-1A receptor, in preclinical development
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CuraSen Therapeutics
Inscopix
HQ: United States
Website
- Description: Provider of neural activity imaging solutions for freely behaving subjects, enabling links between circuit dynamics and behavior. Offers the nVue dual-color system with expanded storage for longitudinal studies, the LScape module for wider field of view and longer working distance in cortical imaging, and Multicolor Data Processing software for streamlined miniscope analysis with PCA/ICA or CNMFe, filtering, and longitudinal registration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inscopix company profile →
Vanda Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies focused on central nervous system disorders, developing and commercializing innovative products through clinical and commercial stage programs, including HETLIOZAccess: an expanded access program for Non-24-Hour Sleep-Wake Disorder (Non-24).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vanda Pharmaceuticals company profile →
Brain Scientific
HQ: United States
Website
- Description: Provider of high-tech, clinical-grade neurological diagnostic devices designed to extend the reach and capability of telemedicine in neurology (teleneurology).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Brain Scientific company profile →
Axsome Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for neurological disorders, including Auvelity for major depressive disorder and Sunosi to improve wakefulness in adults with excessive daytime sleepiness due to obstructive sleep apnea or narcolepsy; developing AXS-05 for Alzheimer’s disease agitation and smoking cessation, AXS-07 for acute migraine, and AXS-12 for narcolepsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Axsome Therapeutics company profile →
Seelos Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapeutics, including: SLS-002 intranasal ketamine for acute suicidal ideation/behavior in MDD and PTSD; SLS-005 IV trehalose for ALS and spinocerebellar ataxia; SLS-009 targeting mutant/misfolded proteins in Huntington’s and Alzheimer’s via autophagy; SLS-004 SNCA gene therapy for Parkinson’s; SLS-007 peptide targeting alpha-synuclein aggregation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Seelos Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CuraSen Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CuraSen Therapeutics
2.2 - Growth funds investing in similar companies to CuraSen Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CuraSen Therapeutics
4.2 - Public trading comparable groups for CuraSen Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →